Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 15/20 | 0.50 |
| ▸ | ATRIP | Q8WXE1 | 9/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 8/20 | 0.50 |
| ▸ | PDCD1 | Q15116 | 8/20 | 0.50 |
| ▸ | CD274 | Q9NZQ7 | 8/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.50 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11898377 | 1.00 | ATR (0.50) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL3597219 | 0.91 | PIK3CA (0.51) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL740079 | 0.91 | PIK3CA (0.53) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL3594425 | 0.89 | ATR (0.49) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL3590480 | 0.86 | PIK3CA (0.48) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL24173907 | 0.85 | PIK3CA (0.63) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL11898379 | 0.85 | PIK3CA (0.63) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL738503 | 0.85 | PIK3CA (0.63) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL3595940 | 0.84 | PIK3CA (0.49) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL8219150 | 0.84 | HRH4 (0.44) | ATRATRIPPIK3CAPIK3R1MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2057140-B1 | MORPHOLINO PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2012-08-08 | — | — | EP | disclosed |
| US-7750003-B2 | Compounds-943 | ASTRAZENECA AB (SE) | 2010-07-06 | — | — | US | disclosed |
| US-7750003-B2 | Compounds-943 | ASTRAZENECA AB (SE) | 2010-07-06 | — | — | US | disclosed |
| US-7750003-B2 | Compounds-943 | ASTRAZENECA AB (SE) | 2010-07-06 | — | — | US | disclosed |
| EP-2057140-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2009-05-13 | — | — | EP | disclosed |
| US-20080171743-A1 | Transcutaneous immunostimulation | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| US-20080171743-A1 | Transcutaneous immunostimulation | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| US-20080171743-A1 | Transcutaneous immunostimulation | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| WO-2008023159-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171743-A1 | Transcutaneous immunostimulation | NFATC1, TLR9, MTOR | ATR 1452/4885ATRIP 4422/4885CHEK1 792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.